Hep C Discussion Forum

Members Login
Username 
 
Password 
    Remember Me  
Chatbox
Please log in to join the chat!
Post Info TOPIC: F3's and Ultrasound following


Moderator

Status: Offline
Posts: 892
Date:
RE: F3's and Ultrasound following
Permalink  
 


Hi C.  thanks for th posting.  The 70% drop after SVR is so great to see.   RC



__________________

 M-61 (3 Treatments)( SOF-RIBA 2014)(SOF-RIBA-PEG 2016)(HCC 2016) (LIVER TRANSPLANT 8-2017)(VOSEVI-RIBA 2017) On my way to SVR.    SVR-12. 3-13-18



Guru

Status: Offline
Posts: 2893
Date:
Permalink  
 

Excerpt of opinion from a well-known American liver doc - he portrays a further "case" situ, but I highlight only the nucleus of his rationale in how he follows his hepc pts.:

 

PS - I have always appreciated this particular docs careful approach to certain issues, for example how he handles core positive only hepb pts. Nice, when you can't be too careful how you screen and follow your hepc pts.!  : ) 

 

" ... For patients who have achieved cure, our emphasis must shift from eradicating viral disease to managing liver disease. The complications of advanced fibrosis and cirrhosis are reduced following SVR but do not disappear completely. In particular, we must be aware of the persistent elevated risk for HCC in patients with cirrhosis or F3 fibrosis.

 

Data from the interferon treatment era and, more recently, from the current direct-acting antiviral era demonstrate that patients with HCV infection are at risk for developing HCC and that achievement of SVR reduces this risk - in both cirrhotic and noncirrhotic patients - by approximately 70%, although the absolute risk of development of HCC in those without cirrhosis is substantially lower than in those with cirrhosis. Both the AASLD/IDSA and EASL guidelines recommend that patients with F3-F4 fibrosis be monitored for HCC by ultrasonography every 6 months following achievement of SVR. Until further data are generated, this HCC screening should continue indefinitely. I would recommend screening the case patient in this way, as he had F3 fibrosis prior to direct-acting antiviral therapy.

 ... we are now doing fewer liver biopsies to stage fibrosis, instead relying on elastography and serum markers of fibrosis. It is hoped that with additional risk stratification models and improved biomarkers, we will be able to better identify those at highest risk for developing HCC, allowing screening to be fine-tuned to target populations most likely to develop HCC. For now, all patients who are evaluated for hepatitis C and determined to have F3 or F4 fibrosis should be screened twice annually with ultrasound following SVR, regardless of how fibrosis was assessed ... "

 



__________________

HCV/HBV 1973. HBV resolved. HCV undiagnosed to 2015. 63 y.o. F. Canada.

GT3a, Fibroscan F3/12 kPa - F4/12.6 kPa, VL log 7.01 (10,182,417), steatosis, high iron load.

SOF/VEL with/without GS-9857 trial - NCT02639338.

SOT March 10 - EOT May 5, 2016 - SOF/VEL/VOX 8 week trial.

 

(SEE UPDATES IN BIO)

Page 1 of 1  sorted by
 
Quick Reply

Please log in to post quick replies.

Legal Disclaimer:

THIS FORUM, IT'S OWNERS, ADMINISTRATORS, MODERATORS AND MEMBERS DO NOT AT ANY TIME GIVE MEDICAL ADVICE AND IN ALL CASES REFER ANYONE HERE TO SEEK APPROPRIATE MEDICAL ADVICE FROM THEIR DOCTOR.